Introducing a recurrent but previously uncharacterized p53 point mutation (Q97*) resulted in tumor generation, demonstrating the oncogenic function of this mutation and the compatibility of CRISPR base editing with the EPO-GEMM platform (Extended Data Fig. 3q–s). Here, EPO is linked to neoplasm.